We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
Read MoreHide Full Article
Key Takeaways
AC Immune stock rises 16.3% after amending its collaboration deal with Eli Lilly.
The revised pact adds next-generation Tau Morphomer candidates and backup compounds to ACIU's pipeline.
ACIU gains CHF 10M upfront, with potential CHF 1.7B milestones and low double-digit royalties.
Shares of AC Immune SA (ACIU - Free Report) have surged 16.3% over the past week, primarily driven by the announcement of an amendment to the Morphomer Tau license and collaboration agreement with Eli Lilly and Company (LLY - Free Report) .
Background of the Morphomer Tau Agreement With LLY
A multi-year collaboration agreement between Lilly and AC Immune was announced in 2018 to research and develop Tau aggregation inhibitor small-molecules for the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. The collaboration brought together ACIU’s proprietary Morphomer platform with Lilly’s expertise in the clinical development and commercialization of therapies for central nervous system disorders.
Per the agreement, ACIU is conducting early-stage development of its Morphomer Tau aggregation inhibitors, while Lilly will enjoy global commercialization rights for these therapies in AD.
Morphomer Tau candidates are designed to be orally administered and efficiently penetrate the brain, while selectively targeting the disease-related form of Tau protein.
Over the past year, shares of ACIU have surged 116.9% compared with the industry’s 30.6% growth.
Image Source: Zacks Investment Research
Amendment Strengthens Long-Term Outlook for Morphomer Platform
The revised agreement further extends ongoing research efforts to include the development of next-generation Tau Morphomer candidates, along with potential backup compounds, broadening the pipeline. Investigational new drug-enabling studies are anticipated to begin in the first half of 2026.
Under the amended agreement, ACIU is entitled to receive an upfront payment of CHF 10 million, along with an additional milestone payment tied to the initiation of phase I dosing, in addition to previously agreed milestone payments. The company is also eligible for more than CHF 1.7 billion in potential development, regulatory and commercial milestone payments, along with tiered royalties in the low double-digit range on future sales, as previously disclosed.
The company received its first milestone payment of CHF 30 million in September 2019 from LLY.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 8.4% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have lost 11% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
Key Takeaways
Shares of AC Immune SA (ACIU - Free Report) have surged 16.3% over the past week, primarily driven by the announcement of an amendment to the Morphomer Tau license and collaboration agreement with Eli Lilly and Company (LLY - Free Report) .
Background of the Morphomer Tau Agreement With LLY
A multi-year collaboration agreement between Lilly and AC Immune was announced in 2018 to research and develop Tau aggregation inhibitor small-molecules for the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. The collaboration brought together ACIU’s proprietary Morphomer platform with Lilly’s expertise in the clinical development and commercialization of therapies for central nervous system disorders.
Per the agreement, ACIU is conducting early-stage development of its Morphomer Tau aggregation inhibitors, while Lilly will enjoy global commercialization rights for these therapies in AD.
Morphomer Tau candidates are designed to be orally administered and efficiently penetrate the brain, while selectively targeting the disease-related form of Tau protein.
Over the past year, shares of ACIU have surged 116.9% compared with the industry’s 30.6% growth.
Image Source: Zacks Investment Research
Amendment Strengthens Long-Term Outlook for Morphomer Platform
The revised agreement further extends ongoing research efforts to include the development of next-generation Tau Morphomer candidates, along with potential backup compounds, broadening the pipeline. Investigational new drug-enabling studies are anticipated to begin in the first half of 2026.
Under the amended agreement, ACIU is entitled to receive an upfront payment of CHF 10 million, along with an additional milestone payment tied to the initiation of phase I dosing, in addition to previously agreed milestone payments. The company is also eligible for more than CHF 1.7 billion in potential development, regulatory and commercial milestone payments, along with tiered royalties in the low double-digit range on future sales, as previously disclosed.
The company received its first milestone payment of CHF 30 million in September 2019 from LLY.
AC Immune Price and EPS Surprise
AC Immune price-eps-surprise | AC Immune Quote
ACIU’s Zacks Rank & Other Stocks to Consider
AC Immune SA currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 8.4% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have lost 11% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.